Abstract
Roxadustat, recently approved, is a hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. This article reviews main features and possible effects by activation of pathway sequences HREs.
Keywords:
EPO; Roxadustat; hypoxia-inducible factor; inflammation; oxidative stress.
Copyright by Società Italiana di Nefrologia SIN, Rome,Italy.
MeSH terms
-
Anemia* / drug therapy
-
Anemia* / etiology
-
Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors
-
Basic Helix-Loop-Helix Transcription Factors / metabolism
-
Glycine / analogs & derivatives
-
Glycine / therapeutic use
-
Humans
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Isoquinolines / therapeutic use
-
Molecular Targeted Therapy
-
Prolyl-Hydroxylase Inhibitors / pharmacology
-
Prolyl-Hydroxylase Inhibitors / therapeutic use
Substances
-
roxadustat
-
Isoquinolines
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Glycine
-
HIF1A protein, human
-
Prolyl-Hydroxylase Inhibitors
-
Basic Helix-Loop-Helix Transcription Factors